Watch this instructive video where Dr. Veronica Flood discusses the benefits of prophylaxis for the treatment of von Willebrand disease (VWD) — who should consider it, the clinical data supporting the efficacy of prophylaxis, its risks and benefits, the selection of a dosing regimen, the importance of monitoring factor levels, the risk of inhibitor development, and unmet clinical and research needs.
Prophylaxis, or the proactive prevention of bleeding, has long been an accepted form of treatment in hemophilia. Now it is recommended in the treatment of VWD for people who experience severe bleeding, including joint bleeds, heavy menstrual bleeding, gastrointestinal bleeding, and more.1 Prophylaxis can improve quality of life, reducing the amount of bleeding, and possibly the amount of treatment required for individual bleeding events.1-4
Prophylaxis, or regular, proactive factor treatment to help reduce the frequency of bleeds by preventing them before they happen, can help people living with VWD manage their illness and stay ahead of symptoms.
1. Connell NT et al. Blood Adv. 2021;5(1):301-325.
2. Miesbach W, Berntorp E. Thromb Res. 2021;199:67-74.
3. James P et al. UpToDate. https://www.uptodate.com/contents/von-willebrand-disease-vwd-treatment-of-major-bleeding-and-major-surgery, (acc. 06/2025).
4. Du P et al. Clin Appl Thromb Hemost. 2022;28:1-8.
|
|
|
© 2026 Octapharma USA, Inc.
All Rights Reserved
Todos los derechos reservados
|